A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Exclusion Criteria

• •1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
• •2. Clinically significant cardiovascular disease.
• •3. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast
• •4. History of severe bleeding disorder or history of spontaneous bleeding requiring blood transfusion or other medical intervention
• •5. History of stroke or intracranial hemorrhage within 180 days before first dose of study drug
• •6. Severe or debilitating pulmonary disease
• •7. Active fungal, bacterial, and/or viral infection requiring systemic therapy
• •8. Known central nervous system involvement by leukemia or lymphoma
• •9. Known infection with HIV or active viral hepatitis B or C infection
• •10. Moderate or severe hepatic impairment, ie, Child-Pugh class B or C
• •11. Major surgery within 4 weeks of the first dose of study drug
• •12. Prior treatment with a (Burton's Kinase) BTK inhibitor
• •13. Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1
• •14. Pregnant or lactating women
• •15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug
• •16. Hypersensitivity to zanubrutinib, ibrutinib, or any of the other ingredients in either drug
• •17. Concurrent participation in another therapeutic clinical trial